Sign inJoin waitlistJoin the waitlist

Kristen Pierce

Physician · University of Vermont Medical Center

Credentials: · ·

History

University of Vermont Medical Center
2019–Present

Infectious Disease
Robert Larner College of Medicine
2009–2011
Internal Medicine
University of Vermont Medical Center
2006–2009
University of Colorado School of Medicine
2003–2006
The Robert Larner, M.D. College of Medicine at the University of Vermont
1999–2003

Research

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model
Science Translational Medicine · 2016 · 208 citations
Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy,…
The Journal of Infectious Diseases · 2015 · 166 citations
Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3
Blood · 2019 · 156 citations

Beth Kirkpatrick
28 papers
Anna Durbin
19 papers
NH
Noreen Hynes
5 papers
Caroline Lyon
4 papers · 1 as a resident
DT
David Tribble
4 papers
KS
Kanta Subbarao
4 papers
KS
Katrin Sadigh
4 papers
Mary Walsh
4 papers
Christopher Huston
3 papers
MD
Matthew Delacruz
3 papers
DG
Dore Guptil
2 papers
ED
Erik Dill
2 papers

Grants

Translational Global Infectious Diseases Research Center
National Institute of General Medical Sciences · P20
Project lead · $2.3M · University of Vermont & St Agric College
2018–2028

Clinical trials

Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
Principal investigator · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2018–2022
Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Principal investigator · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2015
Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)
Principal investigator · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2015
Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine
Principal investigator · Completed · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
2016